LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Kodu・Aktsiate loetelu・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Suletud

SektorTervishoid

71.48 0.15

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

70.67

Max

71.85

Põhinäitajad
By Trading Economics
Sissetulek	292M 150M
Müük	-75M 377M
P/E Sektori keskmine	23.909 49.888
Aktsiakasum	1.221
Kasumimarginaal	39.832
Töötajad	423
EBITDA	-63M 218M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+19.83% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	432M 8.1B
Eelmine avamishind	71.33
Eelmine sulgemishind	71.48

Uudiste sentiment

By Acuity

33%

67%

92 / 344 Pingereas Healthcare

Halozyme Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuni 2026, 19:20 UTC

Suurimad hinnamuutused turgudel

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. juuni 2026, 21:27 UTC

Tulu

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. juuni 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. juuni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. juuni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. juuni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. juuni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. juuni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. juuni 2026, 18:33 UTC

Omandamised, ülevõtmised, äriostud

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. juuni 2026, 17:50 UTC

Tulu

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. juuni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. juuni 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 15:44 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. juuni 2026, 15:25 UTC

Tulu

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. juuni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. juuni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. juuni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. juuni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Halozyme Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

19.83% tõus

12 kuu keskmine prognoos

Keskmine 85.8 USD 19.83%

Kõrge 96 USD

Madal 70 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Halozyme Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Halozyme Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

92 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.